Skip to content
Grand Reels Point

The Global Health Body Issues Alert Over Critical Lack of Weight-Loss Injections

Less than 10% of patients eligible to benefit from GLP-1 drugs including Wegovy can access them, states the WHO as it publishes its initial recommendations on the medications.

With over a billion people worldwide now obese, it is advocating for broader and more equitable access to these injectable treatments.

According to forecasts, more than two billion could be obese by 2030 if no action is taken.

"The new guidelines affirms that obesity is a lifelong illness that can be treated with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the injections that can aid individuals in losing considerable body mass, notes the agency.

Weight-Loss Drug Scarcity

Even in the present best projected outlook, the manufacturing of these medications would only suffice for approximately 100 million people – less than 10% of those who need them, per the health organization.

The advice urges countries and companies to widen availability, through approaches including voluntary licensing.

Exclusive production rights on semaglutide – the main component of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.

How Obesity Drugs Operate

GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and enhance satiety so individuals eat less.

Individuals commonly start to lose weight within a few weeks of commencing the weekly injections.

Research indicates users may see weight return after a year of stopping the drug, as their typical hunger come back.

Being carrying excess weight elevates your chance for contracting health problems, like type 2 diabetes, heart disease, stroke, and some cancers.

Excess weight concerns individuals in every country and was associated with millions of deaths worldwide in 2024, per the WHO.

About the author

Christine Montgomery

A seasoned gaming analyst with over a decade of experience in casino reviews and strategy development.

Grand Reels Point

Type to search articles.